Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
07:00am, Wednesday, 28'th Jul 2021
ELUNATE ® in-market sales 1 rose 186%, reflecting impact of in-house sales force
Hutchmed moves higher after clinical trial link-up with AstraZeneca
03:58am, Wednesday, 28'th Jul 2021
Pharmaceutical group Hutchmed (China) Ltd is in demand after news of a new trial for a key product. It has linked up with AstraZeneca PLC for a Phase II study for Orphathys (savolitinib) at the Beijin
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
08:00pm, Tuesday, 27'th Jul 2021
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification �
Stabilizing Actions and End of Stabilization Period in connection with the Global Offering
07:00am, Friday, 23'rd Jul 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that the st
Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine Tumors
06:46am, Friday, 16'th Jul 2021
The European Medicines Agency (EMA) has validated and accepted Hutchmed (China) Limited's (NASDAQ: HCM) marketing application seeking approval for surufatinib for pancreatic and extra-pancreatic (n
HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency
08:00pm, Thursday, 15'th Jul 2021
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –
Hutchmed Gets $25M In Sales Milestone Payment For Orpathys From AstraZeneca
06:50am, Tuesday, 13'th Jul 2021
Hutchmed (China) Limited (NASDAQ: HCM) announces the first commercial sale in China of Orpathys (savolitinib), a selective small-molecule inhibitor of MET, a receptor tyrosine kinase. It follows le
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
02:00am, Tuesday, 13'th Jul 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in Chi
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering
09:52am, Monday, 12'th Jul 2021
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exer
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
07:00pm, Monday, 05'th Jul 2021
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., July 05, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL-295, its inves
HUTCHMED to Announce 2021 Half-Year Financial Results
04:30am, Friday, 02'nd Jul 2021
HONG KONG and SHANGHAI, China and & FLORHAM PARK, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results fo
U.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
06:00am, Thursday, 01'st Jul 2021
– U.S. FDA has assigned a target action date of April 30, 2022 –
HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong
05:00am, Wednesday, 30'th Jun 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing o
Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO
12:06pm, Wednesday, 23'rd Jun 2021
Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market. Hutchmed expects to spend $300 million on R&D this
HUTCHMED Announces Pricing of Global Offering
10:22am, Wednesday, 23'rd Jun 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing o
